Transcript presentation source - corporate

Changing the Course of Cancer Therapy
AltaRex (TSE:AXO)
In Registration
A Prospectus has been filed with the Ontario Securities Commission for a public offering of
Common Shares
Safe Harbor Statement
This presentation contains forward-looking statements that involve risks and uncertainties,
which may cause actual results to differ materially from the statements made. For this
purpose, any statements that are contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. Without limiting the foregoing, the words
“believes”, “anticipates”, “plans”, “intends”, “expects” and similar expressions are intended
to identify forward-looking statements. Such risks and uncertainties include, but are not
limited to, the need for capital, changing market conditions, completion of clinical trials,
patient enrollment rates, uncertainty of preclinical trial results, the establishment of
manufacturing processes and new corporate alliances, the timely development, regulatory
approval and market acceptance of the Company’s products, litigation, proprietary rights,
patent protection and other risks detailed from time-to-time in the Company’s filings with the
United States Securities and Exchange Commission and Canadian securities authorities.
A L T A R E X
AltaRex Business Model




Focus exclusively on antibodies
Utilize the Company’s AIT® assay platform to
accelerate clinical candidate selection
Focus initially on cancer, subsequently on
infectious and autoimmune diseases
Realize value through partnerships and/or
JVs (or by directly marketing in North
American niche markets)
A L T A R E X
Monoclonal Antibodies


Nine U.S. regulatory approvals in the last 5 years
First year Rituxan® & Herceptin® >$150MM; both set new standards
– Reasons for success include a relative lack of toxicity

1999 therapeutic antibody market @ $1.3 billion
3500
3000
2500
Sales (MM$)
2000
1500
1000
500
0
1994 1995 1996 1997 1998 1999 2000 2001 2002
Monoclonal Antibody Sales
Hambrecht & Quist Industry Report 1999
Year
A L T A R E X
Partnering Strategy
Think globally, act locally



Niche markets: four AIT® cancer antibodies;
ROFO for new cancer antibodies
Partner makes equity investment in AltaRex at
a premium to market price
Identify and consummate joint ventures with
established and “local” marketing/sales
organizations with biotech success
A L T A R E X
Partnering Strategy
Think globally, act locally


AltaRex conducts global development
program including manufacturing
For North America and Northern Europe:
- JV for OvaRex™ (like niche markets)
or
- Multiple cancer antibodies, share 50:50
worldwide development costs
A L T A R E X
Partnering Strategy
Think globally, act locally




“Local” development or pan-European
development conducted and paid for by
“local” partners on pro-rata basis
“Local” registration and pricing support
“Local” sales and marketing efforts by
partner
Net operating profits split 50:50 upon
commercialization
A L T A R E X
Partnering Strategy
Worldwide OvaRex™ sales potential - U.S. $800MM+ (Company estimate)
North America
Germany
France
Italy
Japan
Scandinavia
Spain, Portugal
U.K.
Greece, Balkans
Australia/New Zealand
Benelux
Korea
Israel
ROW
Global Sales (%)
63%
10%
5%
4%
4%
3%
3%
3%
2%
1%
<1%
<1%
<1%
<1%
100%
A L T A R E X
AltaRex Elucidates OvaRex™ Mechanism of
Action at Scientific Conferences






American Society of Hematology - New Orleans (Dec.)
Society of Gynecological Oncologists - San Diego (Feb.)
American Association for Cancer Research
- San Francisco (April)
Immunology 2000 - Seattle (May)
American Society of Clinical Oncology (May)
Future Trends in Therapeutic Antibodies - London (June)
A L T A R E X
Immunity and Cancer



Immune system potent guardian
Usually able to control early-stage tumors
Late-stage tumors “inactivate” the immune
system by:
– Shedding “self ” tumor antigens generating
tolerance (not recognized as foreign) and
immunosuppression
– Secreting inhibitory cytokines
A L T A R E X
How Can OvaRex™ MAb
Augment Cancer Immunity?





Low dose stimulation of immune system with foreign
molecule (mouse protein) that binds tumor antigen
Transportation of the antigen to antigen presenting
cells (enhanced in presence of HAMA)
Enhanced antigen processing and activation of T and
B cells
Activation of co-stimulating cytokines
Removal of immune suppressive tumor antigens
A L T A R E X
OvaRex™ MAb Summary





Targets TAA CA125 over-expressed >80% of late-stage
ovarian cancer patients
Ovarian cancer devastating (few symptoms; late diagnosis;
high mortality)
OvaRex™ data from relapsed patents (target indication)
evidence efficacy and safety in phase II trials
Double-blind placebo-controlled or controlled trials ongoing
in “watchful waiting” (target indication); Fast Track
obtained
Registration plans for North America & Europe (including
bridging to state-of-the-art manufacturing)
A L T A R E X
AIT® Pipeline
One antibody, multiple tumors…one tumor, multiple antigens
DISCOVERY
PRECLINICAL
PHASE I
OvaRex™
Ovarian
AR54
Ovarian
BrevaRex™
Multiple myeloma
GivaRex™
GI
ProstaRex™
Prostate
Antiviral/Autoimmune
Multiple Opportunities
A L T A R E X
PHASE II/III
In Summary
AIT® Technology platform:
 Novel and safe therapeutic approach
 Multiple targets for cancer immunotherapy
 Potent method to induce tumor killing
 Product pipeline established
 Discovery assay system for future opportunities
 OvaRex™ in late-stage clinical development with
near-term commercial potential
A L T A R E X